Back to top
more

Conatus Pharmaceuticals Inc. (CNAT)

(Delayed Data from NSDQ)

$0.90 USD

0.90
746,677

+0.05 (5.88%)

Updated May 3, 2019 03:59 PM ET

After-Market: $0.90 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Conatus (CNAT) Loss Narrower Than Expected in Q4, Sales Miss

Conatus (CNAT) reports narrower-than-expected loss in Q4 while revenues marginally fall short of estimates. However, the top line shows a massive year-over-year increase.

    What's in Store for Conatus (CNAT) This Earnings Season?

    Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q4. However, the company's portfolio lacks an approved product and its revenue generation.

      Conatus (CNAT) Loss Wider Than Expected in Q3, Sales Miss

      Conatus (CNAT) reports wider-than-expected loss in Q3. However, revenues significantly increased year over year.

        What's in Store for Conatus (CNAT) This Earnings Season?

        Conatus' (CNAT) progress with lead candidate emricasan might boost the stock in Q3. However, the company's current portfolio shows no approved product and revenue generation.

          Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU

          Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.

            Conatus Entrusts Keith W. Marshall With Key Management Roles

            Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.

              Non-Alcoholic Steatohepatitis 2017 Progress Update

              Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).

                Will Conatus Liver Disease Candidate Drive Long-Term Growth?

                Conatus' (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in the company's portfolio are a positive step toward driving growth.

                  Conatus (CNAT) Up 7% Since Earnings Report: Can It Continue?

                  Conatus (CNAT) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    Will Conatus Key Candidate Emricasan Drive Long-Term Growth?

                    Conatus's (CNAT) efforts to develop lead candidate emricasan in absence of an approved product in its portfolio are a positive step by the company to propel growth.

                      Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates

                      Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits.

                        What's in Store for Conatus (CNAT) this Earnings Season?

                        Conatus' (CNAT) aim to progress with its lead candidate emricasan might boost the stock in Q2 results, although the company's current portfolio shows no approved product and revenue generation.

                          Company News for June 27, 2017

                          Companies in the News are: SCHN,ARNC,CAR,CNAT

                            Conatus's PSC Candidate Gets Orphan Designation in the U.S.

                            Conatus Pharmaceuticals Inc. (CNAT) announced FDA's grant of Orphan Drug Designation (ODD) to its pipeline candidate IDN-7314 for treatment of primary sclerosing cholangitis.

                              Conatus (CNAT) Down 33.1% Since Earnings Report: Can It Rebound?

                              Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                Arpita Dutt headshot

                                Biotech Stock Roundup: Regeneron, BioMarin Report Q1, Kite Down on Patient Death

                                Kite's (KITE) shares were hit by news regarding a patient death resulting from cerebral edema.

                                  Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates

                                  Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents.

                                    What's in the Cards for Inovio (INO) This Earnings Season?

                                    Inovio Pharmaceuticals, Inc. (INO) is scheduled to report first-quarter 2017 results, after market closes. The company incurred wider-than-expected loss in the last quarter.

                                      Kite Pharma (KITE) Q1 Earnings: Is a Surprise in the Cards?

                                      Kite Pharma, Inc. (KITE) is expected to report first-quarter 2017 results on May 8 before the market opens.

                                        Puma Biotechnology (PBYI) Q1 Earnings: Stock to Disappoint?

                                        Puma Biotechnology, Inc. (PBYI) is expected to report first-quarter 2017 results later this month.

                                          Jazz Pharma (JAZZ) Q1 Earnings: Stock Likely to Disappoint?

                                          Jazz Pharmaceuticals plc (JAZZ) is scheduled to report first-quarter 2017 results on May 9, after the market closes.

                                            Is ImmunoGen (IMGN) Poised for a Beat this Earnings Season?

                                            ImmunoGen, Inc. (IMGN) is scheduled to report first-quarter 2017 results on May 5, before the opening bell.

                                              Can Conatus Pharma (CNAT) Deliver a Beat in Q1 Earnings?

                                              We expect Conatus Pharmaceuticals Inc. (CNAT) to beat expectations when it reports first-quarter 2017 results on May 4, after the market closes.

                                                Conatus (CNAT) Catches Eye: Stock Moves Up 10% in Session

                                                Conatus Pharmaceuticals Inc. (CNAT) moved big last session, as its shares rose almost 10% on the day.

                                                  Conatus (CNAT) Up 57.7% Since Earnings Report: Can It Continue?

                                                  Conatus (CNAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.